A single-center, prospective, open-labelled, randomized clinical trial of Tixagevimab/Cilgavimab for COVID-19 in Immunocompromised Children and Adolescents
Latest Information Update: 26 Apr 2024
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Tozinameran
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 26 Apr 2024 New trial record
- 06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024